FDA Approves Supplemental Application for TYENNE (Tocilizumab-AAZG)
The FDA has approved a supplemental application for TYENNE, a formulation of Tocilizumab-AAZG, submitted by Fresenius Kabi USA.
Asset / Drug
Drug and asset intelligence for TYENNE with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
IL-6 Inhibitor
No catalysts indexed for this entity yet.
July 20, 2026 · N/A
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.